Enhanced patient involvement and the need to revise the core set - Report from the psoriatic arthritis working group at OMERACT 2014

Journal of Rheumatology

Volumn 42, Issue 11, 2015, Pages 2198-2203

  Tillett, William ^a   Eder, Lihi ^b,c   Goel, Niti ^f   De Wit, Maarten ^d   Gladman, Dafna D ^c   FitzGerald, Oliver ^e   Campbell, Willemina ^f   Helliwell, Philip S ^g   Gossec, Laure ^h   Orbai, Ana Maria ⁱ   Ogdie, Alexis ^j   Strand, Vibeke ^j   McHugh, Neil J ^a,k   Mease, Philip J ^l,m  

^a ROYAL NATIONAL HOSPITAL FOR RHEUMATIC DISEASES   (United Kingdom)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d Duke University School of Medicine ^*  (Netherlands)

^e ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF LEEDS   (United Kingdom)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k University of Bath   (United Kingdom)

^l UNIVERSITY OF WASHINGTON   (United States)

^m HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

Omeract; Outcome measurement; Patient participation; Psoriatic arthritis

Indexed keywords

ARTHRITIS; ARTICLE; DACTYLITIS; DISEASE ACTIVITY; ENTHESITIS; FATIGUE; FUNCTIONAL DISEASE; HUMAN; MUSCULOSKELETAL DISEASE ASSESSMENT; NAIL PSORIASIS; OUTCOME ASSESSMENT; PATIENT PARTICIPATION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; SOCIAL DISABILITY; SPONDYLITIS; WORK DISABILITY; ARTHRITIS, PSORIATIC; CONSENSUS DEVELOPMENT; FEMALE; LONGITUDINAL STUDY; MALE; OBSERVATIONAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERITY OF ILLNESS INDEX; WASHINGTON;

ANTIRHEUMATIC AGENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; OBSERVATIONAL STUDIES AS TOPIC; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT PARTICIPATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; WASHINGTON;

EID: 84940570558     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.141156     Document Type: Article

References (36)

1. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis: a population-based study. Arthritis Rheum 2009;61:233-9.
2. Gladman DD, Stafford-Brady F, Chang CH, Lewandowski K, Russell ML. Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990;17:809-12.
3. McHugh NJ, Balachrishnan C, Jones SM. Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology 2003;42:778-83.
4. Torre Alonso JC, Rodriguez Perez A, Arribas Castrillo JM, Ballina Garcia J, Riestra Noriega JL, Lopez Larrea C. Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991;30:245-50.
5. de Korte J, Sprangers MA, Mombers FM, Bos JD. Quality of life in patients with psoriasis: a systematic literature review. J Investig Dermatol Symp Proc 2004;9:140-7.
6. Gladman DD, Mease PJ, Strand V, Healy P, Helliwell PS, Fitzgerald O, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167-70.
7. Helliwell PS, Fitzgerald O, Mease PJ, Gladman DD. GRAPPA Responder Index Project (GRACE): a report from the GRAPPA 2011 annual meeting. J Rheumatol 2012;39:2196-7.
8. Mease PJ. Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res 2011;63 Suppl 11:S64-85.
9. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986-91.
10. Helliwell PS, Fitzgerald O, Mease PJ. Development of composite measures for psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J Rheumatol 2012;39:398-403.
11. OMERACT. Guiding principles for patient research partner participation in OMERACT; 2011 v1.0. [Internet. Accessed March 24, 2015.] Available from: www.omeract.org/pdf/2011-03-27%20Agreed%20Patient%20Participation%20Policy.pdf
12. Bingham CO 3rd, Alten R, de Wit MP. The importance of patient participation in measuring rheumatoid arthritis flares. Ann Rheum Dis 2012;71:1107-9.
13. de Wit M, Abma T, Koelewijn-van Loon M, Collins S, Kirwan J. Involving patient research partners has a significant impact on outcomes research: a responsive evaluation of the international OMERACT conferences. BMJ Open 2013;3.
14. de Wit MP, Berlo SE, Aanerud GJ, Aletaha D, Bijlsma JW, Croucher L, et al. European League Against Rheumatism recommendations for the inclusion of patient representatives in scientific projects. Ann Rheum Dis 2011;70:722-6.
15. Tillett W, Adebajo A, Brooke M, Campbell W, Coates LC, FitzGerald O, et al. Patient involvement in outcome measures for psoriatic arthritis. Current Rheumatol Rep 2014;16:418.
16. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis 2014;73:1012-9.
17. de Wit M, Campbell W, FitzGerald O, Gladman DD, Helliwell PS, James J, et al. Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 annual meeting. J Rheumatol 2014;41:1206-11.
18. Gladman DD, Mease PJ, Krueger G, van der Heidje DM, Antoni C, Helliwell PS, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2005;32:2262-9.
19. Coates LC, FitzGerald O, Gladman DD, McHugh N, Mease P, Strand V, et al. Reduced joint counts misclassify patients with oligoarticular psoriatic arthritis and miss significant numbers of patients with active disease. Arthritis Rheum 2013;65:1504-9.
20. Chandran V, Gottlieb A, Cook RJ, Duffin KC, Garg A, Helliwell P, et al. International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. Arthritis Rheum 2009;61:1235-42.
21. Taylor WJ, Mease PJ, Adebajo A, Nash PJ, Feletar M, Gladman DD. Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health. J Rheumatol 2010;37:1885-91.
22. Helliwell PS, Firth J, Ibrahim GH, Melsom RD, Shah I, Turner DE. Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32:1745-50.
23. Gladman DD, Inman RD, Cook RJ, Maksymowych WP, Braun J, Davis JC, et al. International spondyloarthritis interobserver reliability exercise-the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007;34:1740-5.
24. Chandran V, Bhella S, Schentag C, Gladman DD. Functional assessment of chronic illness therapy-fatigue scale is valid in patients with psoriatic arthritis. Ann Rheum Dis 2007;66:936-9.
25. Cauli A, Gladman DD, Mathieu A, Olivieri I, Porru G, Tak PP, et al. Patient global assessment in psoriatic arthritis: a multicenter GRAPPA and OMERACT study. J Rheumatol 2011;38:898-903.
26. Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986-91.
27. Helliwell PS, Kavanaugh A. Radiographic progression is less in patients achieving a good response to treatment as measured by new composite indices of disease activity in psoriatic arthritis: data from an interventional study with golimumab. Ann Rheum Dis 2014;73 Suppl 2:108.
28. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680-5.
29. European League Against Rheumatism. The EULAR RAID and PsAID score. [Internet. Accessed March 25, 2015.] Available from: www.eular.org/tools-products-.cfm?fromSearch=psaid
30. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA, et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. J Clin Epidemiol 2014;67:745-53.
31. Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, et al. Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol 2014;41:1670-4.
32. Sakkas LI, Alexiou I, Simopoulou T, Vlychou M. Enthesitis in psoriatic arthritis. Semin Arthritis Rheum 2013;43:325-34.
33. Gladman DD, Ziouzina O, Thavaneswaran A, Chandran V. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era. J Rheumatol 2013;40:1357-9.
34. Mease P. Psoriatic arthritis and spondyloarthritis assessment and management update. Curr Opin Rheumatol 2013;25:287-96.
35. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
36. Coates LC, Fitzgerald O, Mease PJ, Gladman DD, Strand V, Goel N, et al. Development of a disease activity and responder index for psoriatic arthritis - report of the psoriatic arthritis module at OMERACT 11. J Rheumatol 2014;41:782-91.